However, it did not yield significant improvements in pain perception.[64] GLP-1 receptors have also been detected in the choroid plexus, and in a rodent model, their activation was shown to reduce cerebrospinal fluid secretion and intracranial pressure (ICP).[65] In patients with idiopathic intracranial hypertension (IIH) and obesity, exenatide, semaglutide, liraglutide have been associated with a reduction in the number of headache days, and exenatide significantly reduced ICP.[66, 67] Furthermore, animal studies have indicated potential benefits of GLP-1RAs in neuropathic pain and diabetic neuropathy, although clinical evidence remains inconsistent.[64] One study reported structural improvements in the nerves of patients with diabetic neuropathy receiving semaglutide or dulaglutide, while two other studies found no significant benefit in neuropathy symptoms with liraglutide and exenatide.[6870] Additional off-label uses under investigation include neurodegenerative disorders, polycystic ovary syndrome (PCOS), and osteoporosis
With sensitivity to the physical, emotional, and financial impact these situations can create, our team takes the time to clearly outline expectations, communicate openly, and guide clients through their options with care and respect
The short-term study design was insufficient to prove their effect on visual outcomes
Louisiana has seen a rapid increase in clinics offering GLP-1 medications, and not all of them provide the level of follow-up these treatments require
Wolfe BM, Schoeller DA, McCrady-Spitzer SK, Thomas DM, Sorenson CE, Levine JA
